60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
DaVita HealthCare Partners Inc. stock reached a 52-week low, closing at $114.81, representing a 36% drop from its 52-week high of $179.60. This marks a significant downturn for the company, which has seen its stock price decline by 25.75% over the past year. According to InvestingPro analysis, the stock appears slightly undervalued compared to its Fair Value estimate. The healthcare provider, known for its kidney care services, has faced a challenging market environment, contributing to the downward trend in its stock performance. Despite these challenges, DaVita maintains a "GREAT" overall financial health score and trades at a P/E ratio of 11.98 with a strong free cash flow yield of 16%. Investors are closely monitoring DaVita's strategic moves and market conditions, as the company navigates through these turbulent times. Management has been aggressively buying back shares, one of several insights available in the comprehensive Pro Research Report for DVA and 1,400+ other stocks on InvestingPro.
In other recent news, DaVita HealthCare Partners Inc reported its Q3 2025 earnings, which showed a significant earnings miss and a slight revenue shortfall. The company posted an earnings per share (EPS) of $2.51, falling short of the forecasted $3.23, representing a 22.29% negative surprise. Revenue was reported at $3.42 billion, slightly below the expected $3.44 billion. These results highlight the challenges DaVita is facing in meeting analyst expectations. The earnings miss and revenue shortfall are notable developments for investors to consider. There were no recent upgrades or downgrades reported by analysts. As these are recent developments, they may influence investor sentiment and strategic decisions moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.